Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.

@article{Huang2016SynergisticAE,
  title={Synergistic antidepressant-like effects between a kappa opioid antagonist (LY2444296) and a delta opioid agonist (ADL5859) in the mouse forced swim test.},
  author={Peng Huang and Julia Tunis and Christopher Parry and Ronald J. Tallarida and Lee-Yuan Liu-Chen},
  journal={European journal of pharmacology},
  year={2016},
  volume={781},
  pages={
          53-9
        }
}

Figures from this paper

Rapid-Onset Anti-Stress Effects of a Kappa-Opioid Receptor Antagonist, LY2795050, Against Immobility in an Open Space Swim Paradigm in Male and Female Mice
TLDR
These studies show that a novel KOR-antagonist can produce very rapid onset anti-immobility effects in this model of acute stress exposure, and may be of interest for medication development.
“Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats”
TLDR
It is suggested that acute blockade of KOPr by a relatively short-acting antagonist produces therapeutic-like effects selectively in rats with a history of chronic extended access cocaine self-administration.
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.
TLDR
Findings support a potential role of kappa opioid receptors in mediating the behavioral activity of ketamine and its non-dissociate metabolite (2R,6R)-hydroxynorketamine.
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.
TLDR
While animal studies have indicated that compounds of this structural class are capable of normalizing withdrawal signs in animal models of cocaine and alcohol dependence and reducing cocaine andalcohol intake/seeking, additional studies are needed to determine the value of these second generation KOR antagonists in treating mood disorders and substance use disorders in humans.
Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice
TLDR
This study shows that the κ-receptor system is involved in an ethologically relevant measure of anhedonia, and that λ-selective doses of these antagonists can produce effects consistent with rapid anti-anhedonia.
Delta Opioid Receptors and Modulation of Mood and Emotion.
TLDR
Preclinical and clinical evidence supporting the antidepressant-like effects of opioid ligands, and in particular, delta opioid receptor (DOR) agonists, are explored.
Multifunctional Opioid Ligands.
TLDR
This chapter describes several classes of multifunctional ligands that interact with at least one opioid receptor and the structures, pharmacological utility, and therapeutic drawbacks of these classes of ligands are discussed.
...
...

References

SHOWING 1-10 OF 55 REFERENCES
Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
TLDR
Findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc "triggers" immobility behavior in the FST and raise the possibility that kappa-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects.
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
TLDR
Findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc “triggers” immobility behavior in the FST and raise the possibility that κ-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects.
Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents.
TLDR
It is possible that delta-opioid-receptor agonists might be novel and potent antidepressants that also have anxiolytic-like effects and may play an important role in the regulation of emotional responses.
Antidepressant-Like Effects of the Novel Kappa Opioid Antagonist MCL-144B in the Forced-Swim Test
TLDR
Administration of a novel opioid mixed agonist/antagonist capable of antagonist activity at the KOR would attenuate forced-swim stress (FSS)-induced immobility, an animal model of depression-like behavior, and MCL-144B demonstrated dose- and time-dependent antinociception and KOR-mediated antagonism.
Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats
TLDR
δ-Mediated convulsions do occur in rats and can be prevented without affecting the δ-mediated effects in the forced swim assay.
...
...